Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12620000566932
ACTRN12620000566932
Terminated
Phase 3

BEAT COVID-19: A Bayesian adaptive platform, randomised controlled Trial to evaluate the efficacy and safety of interventions for COVID-19.

niversity of Sydney0 sites195 target enrollmentMay 14, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19Infection - Other infectious diseases

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
COVID-19
Sponsor
niversity of Sydney
Enrollment
195
Status
Terminated
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 14, 2020
End Date
March 19, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Adult, aged greater than or equal to 18 years.
  • •2\.PCR or RAT\-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS\-CoV\-2\) infection.
  • •3\.Intention for community\-based management.
  • •4\.Eligibility to at least one recruiting domain.
  • •5\.Participant \& treating clinician are willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments, and.
  • •6\.Documented informed consent

Exclusion Criteria

  • •1\. Currently pregnant or breast\-feeding
  • •2\. Any medical condition which, in the opinion of the Investigator, may affect the participant’s safety or study participation and conduct

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Software for COVID19 Detection from Chest X-Ray, CT or Ultrasonography
CTRI/2020/07/026351PurplAS IT Services Pvt Ltd
Completed
Not Applicable
ASTERIX: An observational study to identify sub-groups of COVID-19 patients based on their demographic, clinical and laboratory profile, and to determine if these sub-groups can be used to predict severity of disease and response to therapyCOVID-19 (SARS-CoV-2 infection)Infections and Infestations
ISRCTN66141262HS Greater Glasgow and Clyde6,000
Active, not recruiting
Phase 1
Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.
EUCTR2020-001243-15-BEZLeuven200
Active, not recruiting
Phase 1
Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.COVID-19MedDRA version: 20.0Level: LLTClassification code 10038700Term: Respiratory infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-001614-38-BEZLeuven282
Recruiting
Not Applicable
HERALD
PER-106-20CureVac AG,7,448